210 related articles for article (PubMed ID: 18949362)
1. Up-regulation of NK cell function against head and neck cancer in response to ss-isRNA requires TLR7.
Pries R; Wulff S; Kesselring R; Börngen K; Xie L; Wollenberg B
Int J Oncol; 2008 Nov; 33(5):993-1000. PubMed ID: 18949362
[TBL] [Abstract][Full Text] [Related]
2. Neem leaf glycoprotein induces perforin-mediated tumor cell killing by T and NK cells through differential regulation of IFNgamma signaling.
Bose A; Chakraborty K; Sarkar K; Goswami S; Chakraborty T; Pal S; Baral R
J Immunother; 2009 Jan; 32(1):42-53. PubMed ID: 19307993
[TBL] [Abstract][Full Text] [Related]
3. TLR8-driven IL-12-dependent reciprocal and synergistic activation of NK cells and monocytes by immunostimulatory RNA.
Berger M; Ablasser A; Kim S; Bekeredjian-Ding I; Giese T; Endres S; Hornung V; Hartmann G
J Immunother; 2009 Apr; 32(3):262-71. PubMed ID: 19242374
[TBL] [Abstract][Full Text] [Related]
4. Head and neck cancer triggers the internalization of TLR3 in natural killer cells.
Xie L; Pries R; Kesselring R; Wulff S; Wollenberg B
Int J Mol Med; 2007 Oct; 20(4):493-9. PubMed ID: 17786279
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cell mediated cytotoxicity of tumor cells initiated by neem leaf preparation is associated with CD40-CD40L-mediated endogenous production of interleukin-12.
Bose A; Baral R
Hum Immunol; 2007 Oct; 68(10):823-31. PubMed ID: 17961770
[TBL] [Abstract][Full Text] [Related]
6. Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7.
Bourquin C; Schmidt L; Lanz AL; Storch B; Wurzenberger C; Anz D; Sandholzer N; Mocikat R; Berger M; Poeck H; Hartmann G; Hornung V; Endres S
J Immunol; 2009 Nov; 183(10):6078-86. PubMed ID: 19890064
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
[TBL] [Abstract][Full Text] [Related]
8. Decreased levels of circulating regulatory NK cells in patients with head and neck cancer throughout all tumor stages.
Wulff S; Pries R; Börngen K; Trenkle T; Wollenberg B
Anticancer Res; 2009 Aug; 29(8):3053-7. PubMed ID: 19661315
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
van Herpen CM; van der Laak JA; de Vries IJ; van Krieken JH; de Wilde PC; Balvers MG; Adema GJ; De Mulder PH
Clin Cancer Res; 2005 Mar; 11(5):1899-909. PubMed ID: 15756016
[TBL] [Abstract][Full Text] [Related]
10. IFNalpha2b stimulated release of IFNgamma differentially regulates T cell and NK cell mediated tumor cell cytotoxicity.
Bose A; Baral R
Immunol Lett; 2007 Jan; 108(1):68-77. PubMed ID: 17112599
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor interference in myeloid dendritic cells through head and neck cancer.
Frenzel H; Hoffmann B; Brocks C; Schlenke P; Pries R; Wollenberg B
Anticancer Res; 2006; 26(6B):4409-13. PubMed ID: 17201162
[TBL] [Abstract][Full Text] [Related]
12. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity.
Suck G; Branch DR; Smyth MJ; Miller RG; Vergidis J; Fahim S; Keating A
Exp Hematol; 2005 Oct; 33(10):1160-71. PubMed ID: 16219538
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity.
Matsui M; Kishida T; Nakano H; Yoshimoto K; Shin-Ya M; Shimada T; Nakai S; Imanishi J; Yoshimoto T; Hisa Y; Mazda O
Cancer Res; 2009 Mar; 69(6):2523-30. PubMed ID: 19244121
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cell activity in tumor-draining lymph nodes: investigations in patients with malignant melanoma and head and neck cancer.
Micksche M; Vinzenz K; Kokoschka EM; Kokoschka R
Nat Immun Cell Growth Regul; 1985; 4(6):315-27. PubMed ID: 4088287
[TBL] [Abstract][Full Text] [Related]
16. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of natural killer cell activity in vitro against human tumor cells by some plants from Jordan.
Shabsoug B; Khalil R; Abuharfeil N
J Immunotoxicol; 2008 Jul; 5(3):279-85. PubMed ID: 18830888
[TBL] [Abstract][Full Text] [Related]
18. Suppression of natural killer cell activity by serum derived from head and neck cancer patients.
Kumazawa H; Minamino M; Yukawa N; Hess M
Cancer Detect Prev; 1995; 19(6):494-502. PubMed ID: 8925518
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation.
Zhang C; Zhang J; Niu J; Zhang J; Tian Z
Cytokine; 2008 Apr; 42(1):128-36. PubMed ID: 18280748
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of natural killer cell function and risk of metastatic poorly differentiated head and neck cancer.
Schantz SP; Ordonez NG
Nat Immun Cell Growth Regul; 1991; 10(5):278-88. PubMed ID: 1758468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
